Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acusphere, Inc. stock logo
ACUS
Acusphere
$0.00
$0.00
$0.05
N/A-1.52N/AN/A
Aditxt, Inc. stock logo
ADTX
Aditxt
$2.53
+6.8%
$3.23
$2.14
$68.08
$607K1.29343,606 shs180,864 shs
Achaogen, Inc. stock logo
AKAOQ
Achaogen
$0.03
+0.8%
$0.02
$0.00
$0.05
$1.21M-0.81186,196 shs68,500 shs
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
$0.01
$0.01
$0.01
$0.02
N/AN/AN/AN/A
VOQP
VioQuest Pharmaceuticals
$0.00
$0.00
$0.02
N/A-1.44N/AN/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acusphere, Inc. stock logo
ACUS
Acusphere
0.00%0.00%0.00%0.00%0.00%
Aditxt, Inc. stock logo
ADTX
Aditxt
+6.75%+4.98%-18.39%-35.29%-89.96%
Achaogen, Inc. stock logo
AKAOQ
Achaogen
0.00%0.00%0.00%0.00%0.00%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
0.00%0.00%0.00%-50.00%0.00%
VOQP
VioQuest Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acusphere, Inc. stock logo
ACUS
Acusphere
N/AN/AN/AN/AN/AN/AN/AN/A
Aditxt, Inc. stock logo
ADTX
Aditxt
0.8359 of 5 stars
3.52.00.00.00.00.00.6
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/AN/AN/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
VOQP
VioQuest Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acusphere, Inc. stock logo
ACUS
Acusphere
N/AN/AN/AN/A
Aditxt, Inc. stock logo
ADTX
Aditxt
3.00
Buy$61.002,311.07% Upside
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/A
VOQP
VioQuest Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acusphere, Inc. stock logo
ACUS
Acusphere
N/AN/AN/AN/AN/AN/A
Aditxt, Inc. stock logo
ADTX
Aditxt
$640K0.95N/AN/A$67.18 per share0.04
Achaogen, Inc. stock logo
AKAOQ
Achaogen
$8.73M0.14N/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/A$0.04 per shareN/A
VOQP
VioQuest Pharmaceuticals
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acusphere, Inc. stock logo
ACUS
Acusphere
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Aditxt, Inc. stock logo
ADTX
Aditxt
-$32.38MN/A0.00N/A-5,016.31%-1,614.64%-191.28%5/20/2024 (Estimated)
Achaogen, Inc. stock logo
AKAOQ
Achaogen
-$186.51MN/A0.00N/AN/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
-$8.45MN/A0.00N/AN/A-63.75%-57.93%N/A
VOQP
VioQuest Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acusphere, Inc. stock logo
ACUS
Acusphere
N/AN/AN/AN/AN/A
Aditxt, Inc. stock logo
ADTX
Aditxt
N/AN/AN/AN/AN/A
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/A
VOQP
VioQuest Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acusphere, Inc. stock logo
ACUS
Acusphere
N/AN/AN/A
Aditxt, Inc. stock logo
ADTX
Aditxt
N/A
0.27
0.24
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
6.60
6.60
VOQP
VioQuest Pharmaceuticals
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acusphere, Inc. stock logo
ACUS
Acusphere
N/A
Aditxt, Inc. stock logo
ADTX
Aditxt
15.54%
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
VOQP
VioQuest Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Acusphere, Inc. stock logo
ACUS
Acusphere
4.60%
Aditxt, Inc. stock logo
ADTX
Aditxt
1.23%
Achaogen, Inc. stock logo
AKAOQ
Achaogen
7.80%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
VOQP
VioQuest Pharmaceuticals
32.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acusphere, Inc. stock logo
ACUS
Acusphere
118N/AN/ANot Optionable
Aditxt, Inc. stock logo
ADTX
Aditxt
61240,000236,000No Data
Achaogen, Inc. stock logo
AKAOQ
Achaogen
4248.21 millionN/ANot Optionable
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
8N/AN/ANot Optionable
VOQP
VioQuest Pharmaceuticals
3N/AN/ANot Optionable

VOQP, NEVPF, AKAOQ, ACUS, and ADTX Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acusphere logo

Acusphere

OTCMKTS:ACUS
Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.
Aditxt logo

Aditxt

NASDAQ:ADTX
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Achaogen logo

Achaogen

OTCMKTS:AKAOQ
Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.
Abliva AB (publ) logo

Abliva AB (publ)

OTCMKTS:NEVPF
Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

VioQuest Pharmaceuticals

OTCMKTS:VOQP
VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors. VioQuest Pharmaceuticals also provides chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical companies in various stages of a products' lifecycle. The company was founded in 2000 and is headquartered in Basking Ridge, New Jersey.